JC12 Rec'd PCT/PTC 0 4 OCT 2005

				0 1 00 1 2003				
•					MODIFIED PTO/SB/08 A & B (06-03)			
Substitute for Form 1449 A	P. D/DTO			Complete if Kn 1 5 2 0 6 9				
Substitute for Portin 1449 A	a birio			Application Number	NS Entry of PCT/GB2004/001509			
INFORM	FORMATION DISCLOSURE	JRE .	Confirmation Number	0000				
STATEM	ENT BY APPI	JCA	NT	Filing Date	October 4, 2005			
0 - 11 - 1				First Named Inventor	Torsten ALMEN et al			
(use as n	nany sheets as nece	ssary)	Art Unit	0000			
			-	Examiner Name	Unassigned			
Sheet	1	of	1	Attorney Docket Number	Q-90475			

Document Number				PATENT DOCU	JIVIENTS	
Examiner Initials*	Cite No.1	Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documen	
		US 6,040,408		03/21/2000	Koole	
		US 5,902,839		05/11/1999	Lautenschlager et al	
-	-	-				

FOREIGN PATENT DOCUMENTS							
Examiner Cite Initials* No.1	Foreign Patent Document			Publication Date	Name of Patentee or		
	No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		wo	99/62570		12/09/1999	Lidgren et al	
		EP	0 676 212		10/11/1995	Squibb Bristol Myers Co.	
			-				
		†	T				
		†					
$\overline{}$							

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation		
		Vazquez et al, Biomaterials, 20(21):2047-2053 (1999)			

Examiner Signature /Jae Kwak/ Date Considered 04/29/2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.K./

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{*}Applicant, under clusion designation number (optional). *See Yaird Code, of USPTO Potent Decements at over-unopage, VMED P001.04 or in the comment box of this decurrent. *I factor Office that insent the decurrent, but the very letter device (VMPO Standard 17.3). *Fore protect personal decurrents, the final to the personal or the personal comments, the final to the personal or the personal comments. The final to the personal or the personal comments are the final comments and the personal or the personal comments are the personal comments. The final comments are the personal comments